Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks. The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization. Secondary end points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of insulin. RESULTS: A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P<0.001). The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bolus dose of insulin (-2.8 units per day) (P≤0.002 for all comparisons). The rate of severe hypoglycemia was similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respectively). The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotagliflozin group than in the placebo group. The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). CONCLUSIONS: Among patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than in the placebo group. However, the rate of diabetic ketoacidosis was higher in the sotagliflozin group. (Funded by Lexicon Pharmaceuticals; inTandem3 ClinicalTrials.gov number, NCT02531035 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Use of these processes may have contributed to the lower rates of ketoacidosis seen in some of the studies of these agents for adjunctive glycemic management in people with type 1 diabetes (314-316) compared with those that did not include preventative strategies (310,317).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [316]
In the citing paper
“Information on the safety and efficacy of combining MRAs with SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, ∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE participants were prescribed such a combination.153,718,719,721”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“FIDELIO-DKD and FIGARO-DKD excluded patients with a potassium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“The placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease) trials demonstrated for the non-steroidal MRA finerenone that these effects translate into reduced risk of kid”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationSGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer-Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 484
8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Research works printed but not linked: 1
- Lyons SK, Diabetes Care
Cited by
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationSotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
“(23, 60) Lastly, our absolute effect estimates are specific to the recruited trial populations.”
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367
Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2316 · Cited by 379
“However, when using sotagliflozin, the dose reductions observed in the clinical trialswere largely in theprandial ormealassociated insulin (18).”
BackgroundSelf-citationDevelopment of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
“A serious concern is the greater incidence of diabetic ketoacidosis in these patients [65, 69].”
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
“While glucosuria and glycemic benefits were observed in a 2-week dose-ranging T1D study of dapagliflozin, only the T2D-approved doses have been evaluated thus far in phase 3 trials (11,31).”
BackgroundEmerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
Self-citationObesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252
“tors in the treatment of type 1 diabetes (17,19,26), with events often associated with missed insulin doses or insulin pump failure.”
BackgroundYau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1087 · Cited by 243
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
“6%) with no episode of severe hypoglycemia after 24 weeks of treatment (66).”
BackgroundBuse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
“incidence of DKA in patients with T1D (14).”
BackgroundSelf-citationTherapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
Bai, L., Gao, J., Wei, F., Zhao, J., Wang, D., & Wei, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00423 · Cited by 229
“A recent clinical study reported that the glycated hemoglobin levels of oral SGLT1 inhibitors were lower than placebo in patients with type 1 diabetes who were receiving insulin (Garg et al., 2017).”
BackgroundSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
Danne, T., Cariou, B., Banks, P., Brandle, M., Brath, H., Franek, E., Kushner, J. A., Lapuerta, P., McGuire, D. K., Peters, A. L., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0342 · Cited by 186
“In the global inTandem3 study, which involved 1,402 patients with T1D, sotagliflozin significantly reduced HbA1c, weight, and systolic blood pressure (SBP) without increasing severe hypoglycemia, but it was associated with an increased incidence of DKA (14).”
BackgroundInfluentialSelf-citationSotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Cefalo, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., & Giaccari, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0828-y · Cited by 174
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
Technology in the management of type 1 diabetes mellitus — current status and future prospects
Tauschmann, M., & Hovorka, R. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0044-y · Cited by 183
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Pandey, A. K., Okaj, I., Kaur, H., Belley‐Côté, E. P., Wang, J., Oraii, A., Benz, A. P., Johnson, L., Young, J., Wong, J. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022222 · Cited by 164
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 160
“The inTANDEM trials [48,49] studied 1,406 patients with T1DM randomized to sotagliflozin 400 mg or placebo.”
MethodEhrmann, D., Kulzer, B., Roos, T., Haak, T., Al-Khatib, M., & Hermanns, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30042-5 · Cited by 141
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 149
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy
Palmer, B. F., & Clegg, D. J. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.17621120 · Cited by 162
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C., & Zinman, B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13811 · Cited by 114
Perry, R. J., Rabin-Court, A., Song, J. D., CARDONE, R. L., Wang, Y., Kibbey, R. G., & Shulman, G. I. (2019) · Nature Communications · doi:10.1038/s41467-019-08466-w · Cited by 112
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.036 · Cited by 121
Garg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0246 · Cited by 108
Self-citationSGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Ong, H. T., Ting, A. Z. H., Chia, A. Z. Q., Chong, E. Y., Chan, M. Y., Lee, C., et al. (2021) · Obesity · doi:10.1002/oby.23331 · Cited by 109
“Combined SGLT1/SGLT2 inhibitors have shown similar promise in reducing weight and blood pressure (18,20).”
BackgroundNew advances in type 1 diabetes
Subramanian, S., Khan, F. N., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 120
Ever-Increasing Insulin-Requiring Patients Globally
Garg, S. K., Rewers, A. H., & Aktürk, H. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0101 · Cited by 106
Self-citationSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
Defining and characterising diabetic ketoacidosis in adults
Dhatariya, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107797 · Cited by 111
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 140
Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
Seidelmann, S. B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., Puolijoki, H., Ebeling, T., Perola, M., Salomaa, V., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.061 · Cited by 97
“Although data on SGLT1-specific inhibitors are lacking, initial data from Phase II and III clinical trials of a dual SGLT1/SGLT2 inhibitor is consistent with our findings, with an effect size that was similar to the estimated effect size in this Mendelian randomization analysis (35,36).”
Resultvan Raalte, D. H., Bjornstad, P., Persson, F., Powell, D. R., Castro, R. D. C., Wang, P. S., Liu, M., Heerspink, H. J. L., & Cherney, D. Z. I. (2019) · Diabetes Care · doi:10.2337/dc19-0937 · Cited by 99
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., José, P. S., Rubio, M. Á., & Lecube, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s223618 · Cited by 109
Edwards, K., Li, X.-L., & Lingvay, I. (2022) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgac618 · Cited by 85
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 102
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 92
“4% of the patients treated with sotagliflozin vs 0% in the placebo group.(101) If the composition of the microbiome contributes to the severity of intestinal side effects remains to be determined.”
BackgroundA Global Perspective of Latent Autoimmune Diabetes in Adults
Mishra, R., Hodge, K. M., Cousminer, D. L., Leslie, R. D., & Grant, S. F. A. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.07.001 · Cited by 87
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
Yamada, T., Shojima, N., Noma, H., Yamauchi, T., & Kadowaki, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13260 · Cited by 81
“Garg (26) Baker (25) Dandona (27) Bode (22) Kuhadiya (21) Pieber (20) Henry (18) Henry (14)”
InfluentialEffect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
Ye, Y., Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01517 · Cited by 87
“SGLT2 inhibitors exert the same effect in patients with type 1 diabetes mellitus (T1DM), although T1DM is not an indication for SGLT2 inhibitor therapy (Garg et al., 2017).”
BackgroundEfficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Garg, S. K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0490 · Cited by 78
Self-citationSGLT inhibitor adjunct therapy in type 1 diabetes
McCrimmon, R. J., & Henry, R. R. (2018) · Diabetologia · doi:10.1007/s00125-018-4671-6 · Cited by 79
Self-citationRoddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03339-3 · Cited by 93
“Furthermore, the grading for Recommendation number 2 has been increased from 2D to 2C, given evidence available from the InTandem3 trial [54].”
MethodThe Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Fattah, H., & Vallon, V. (2018) · Drugs · doi:10.1007/s40265-018-0901-y · Cited by 83
“Garg (2017) [18] Sotagliflozin 400, placebo No difference between Rx vs placebo 21 vs 4 45 vs 15 25 vs 27 13 vs 2 SGLT2 Inhibition in Type 1 Diabetes 721”
InfluentialStaplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101163 · Cited by 74
“trials (sotagliflozin 21 participants [30/1000 patient-years] versus 4 participants allocated placebo [6/1000patient-years]) [17].”
BackgroundYuan, S., Wang, L., Zhang, H., Xu, F., Zhou, X., Yu, L., Sun, J., Chen, J., Ying, H., Xu, X., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104488 · Cited by 81
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 78
“Sotagliflozin has been established to be effective in T1DM patients uncontrolled with insulin [65].”
BackgroundThe expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Brown, E. E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J. J., & Cuthbertson, D. J. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1841281 · Cited by 80
“Compared to selective SGLT2 inhibitors, sotagliflozin has similar efficacy in terms of glycaemic control and weight loss and despite its increased selectivity for SGLT1 is well tolerated without severe gastrointestinal side effects, most likely due to incomplete SGLT1 inhibition [76].”
BackgroundAdult-onset autoimmune diabetes
Buzzetti, R., Maddaloni, E., Gaglia, J. L., Leslie, R. D., Wong, F. S., & Boehm, B. O. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00390-6 · Cited by 71
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 71
Herrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P. M., Rosano, G. M. C., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 69
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Garg, S. K., Akturk, H. K., Kaur, G., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0050 · Cited by 65
Self-citationEfficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 67
Self-citationAktürk, H. K., Dong, F., Snell‐Bergeon, J. K., Karakus, K. E., & Shah, V. N. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223991 · Cited by 72
Danne, T., Cariou, B., Buse, J. B., Garg, S. K., Rosenstock, J., Banks, P. L., Kushner, J. A., McGuire, D. K., Peters, A. L., Sawhney, S., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2149 · Cited by 66
Self-citationSotagliflozin: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01146-5 · Cited by 64
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
“The gastrointestinal adverse events were of low incidence [76].”
BackgroundMusso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
de Boer, R. A., Núñez, J. E., Kozlovski, P., Wang, Y., Proot, P., & Keefe, D. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14248 · Cited by 63
“Gastrointestinal AEs are commonly reported following treatment with both sotagliflozin and licogliflozin,(18,20) while clinical trials with sotagliflozin have also raised concerns around the risk of hypoglycaemia and diabetic ketoacidosis.(43) No new safety signals were reported in this study, with most AEs limited an…”
BackgroundPalanca, A., van Nes, F., Pardo, F., Ampudia‐Blasco, F. J., & Mathieu, C. (2022) · Diabetes Care · doi:10.2337/dc21-1584 · Cited by 63
Powell, D. R., Zambrowicz, B., Morrow, L., Beysen, C., Hompesch, M., Turner, S., Hellerstein, M. K., Banks, P. L., Strumph, P., & Lapuerta, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz258 · Cited by 64
Self-citationLi, D., Liu, Y.-Y., Hidru, T. H., Yang, X.-L., Wang, Y.-S., Chen, C., Li, K. H. C., Tang, Y.-Q., Wei, Y.-S., Tse, G., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.619586 · Cited by 52
“Sotagliflozin: NCT02531035 (54) 2020 43.”
BackgroundPettus, J., BOEDER, S. C., Christiansen, M. P., Denham, D. S., Bailey, T. S., Aktürk, H. K., Klaff, L. J., Rosenstock, J., Cheng, M., Bode, B. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02011-x · Cited by 62
Self-citationSchnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Skra, J., Valensi, P. E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 60
Prevalence, Cost, and Burden of Diabetic Ketoacidosis
Virdi, N. S., Poon, Y., Abaniel, R. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0149 · Cited by 67
Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Lovshin, J. A., Boulet, G., Lytvyn, Y., Lovblom, L. E., Bjornstad, P., Farooqi, M. A., LAI, V. S., Cham, L., TSE, J. M., Orszag, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96968 · Cited by 57
SGLT1 inhibition: Pros and cons
Tsimihodimos, V., Filippas-Ntekouan, S., & Elisaf, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.019 · Cited by 55
Moradi‐Marjaneh, R., Paseban, M., & Sahebkar, A. (2019) · Phytotherapy Research · doi:10.1002/ptr.6421 · Cited by 55
“Reductions in insulin requirements, weight, and blood pressure are other benefits of sotagliflozin (Garg et al., 2017).”
BackgroundSims, H., Smith, K. H., Bramlage, P., & Minguet, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13645 · Cited by 53
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 52
Past, present and future of latent autoimmune diabetes in adults
Liu, B., Xiang, Y., Liu, Z., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3205 · Cited by 50
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 52
Dejgaard, T., von Scholten, B. J., Christiansen, E., Kreiner, F., Bardtrum, L., von Herrath, M., Mathieu, C., & Madsbad, S. (2021) · Diabetes, obesity and metabolism · doi:10.1111/dom.14532 · Cited by 42
Maffei, P., Bettini, S., Busetto, L., & Dassie, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240903 · Cited by 49
“25 Empagliflozin regulated increased autophagy, which depended on the downregulation of NHE1 and NHE1-related genes that induce autophagy, such as Beclin 1 and autophagy-related protein 5.”
BackgroundOptimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
“Various studies investigated the efficacy of SGLT-2i (empagliflozin [48, 49], dapagliflozin [50, 51], canagliflozin [52] and the dual SGLT-1 and -2i sotagliflozin [53, 54]) in the treatment of T1DM.”
BackgroundHampp, C., Swain, R. S., Horgan, C. E., Dee, E., Qiang, Y., Dutcher, S. K., Petrone, A. B., Tilney, R. C., Maro, J. C., & Panozzo, C. A. (2019) · Diabetes Care · doi:10.2337/dc19-1481 · Cited by 46
“The sotagliflozin clinical trials, referred to as trials 309 (9), 310 (10), and 312 (11), included patients with type 1 diabetes from North America, Europe and Israel, andworldwide, respectively, who were followed for 52 weeks (trials 309 and 310) or 24 weeks (trial 312) to”
BackgroundReducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
SGLT inhibitors for type 1 diabetes: proceed with extreme caution
Wolfsdorf, J. I., & Ratner, R. E. (2019) · Diabetes Care · doi:10.2337/dci19-0008 · Cited by 45
“Importantly, some patients using these medications off-label (14) and study participants (12,13) have presented with euglycemic DKA (near-normal or only”
BackgroundGlucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
BOEDER, S. C., & Edelman, S. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13749 · Cited by 44
“001]).(39) Sotagliflozintreated patients had greater reductions from baseline in A1C and”
BackgroundLü, J., Tang, L., Meng, H., Zhao, J., & Liang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3169 · Cited by 43
Sinclair, A. J., Dunning, T. L., Dhatariya, K., & an International Group of Experts (2019) · Diabetic Medicine · doi:10.1111/dme.14135 · Cited by 44
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41
“Such BP reductions are reported with both SGLT2 inhibitors (20,21) and SGLT1 and 2 inhibitors (22,23), caused by a reduction in plasma volume associated with SGLT inhibition (24), and they are consistent with increases in renal glucose and sodium elimination as well as reduced body weight.”
BackgroundShimada, A., Hanafusa, T., Yasui, A., Lee, G., Taneda, Y., Sarashina, A., Shiki, K., George, J. T., Soleymanlou, N., & Marquard, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13351 · Cited by 42
“0%] vs placebo: 0 participants).(11,12) DKA events (certain/potential) were reported with dapagliflozin (5 mg, 4 [1%]/16 [6%] and 10 mg, 5 [2%]/19 [6%] participants), which represented an increased risk of DKA compared with placebo (3 [1%]/6 [2%] participants) after 24 weeks of treatment.”
Background
Metadata
- Authors
- Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., Danne, T., McGuire, D. K., Kushner, J. A., Peters, A., & Strumph, P.
- Affiliations
- University of Southern California (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-14
- Volume
- 377
- Issue
- 24
- Pages
- 2337-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755899227
- Cited by
- 417
- References
- 34
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 38 · 2023: 36 · 2022: 32 · 2021: 41 · 2020: 57 · 2019: 72 · 2018: 64 · 2017: 10
- FWCI
- 43.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Wayne State University
- Alere
- University of Dundee
- Massachusetts Medical Society
- Intarcia Therapeutics
- Bigfoot Biomedical
- MannKind Corporation
- Dexcom
- AstraZeneca HealthCare Foundation
- University of Leicester
- Eisai
- Novo Nordisk
- Servier
- Mitsubishi Tanabe Pharma Corporation
- Esperion Therapeutics
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, SGLT2 inhibitors, insulin therapy, glycemic control, HbA1c, hypoglycemia, diabetic ketoacidosis, weight loss, systolic blood pressure, insulin dose reduction, combination therapy, drug safety and efficacy, insulin pump, insulin injection
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Least-Squares Analysis, Diabetic Ketoacidosis, Sodium-Glucose Transport Proteins, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.